{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:21:26Z","timestamp":1791091286113,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.ahj.2010.06.039","type":"journal-article","created":{"date-parts":[[2010,9,8]],"date-time":"2010-09-08T04:43:11Z","timestamp":1283920991000},"page":"506-512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":136,"title":["Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events"],"prefix":"10.1016","volume":"160","author":[{"given":"Klaus A.","family":"Tiroch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Sibbing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Roosen-Runge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julinda","family":"Mehilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Sch\u00f6mig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Kastrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2010.06.039_bb0005","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJM199408253310801","article-title":"A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease","volume":"331","author":"Serruys","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2010.06.039_bb0010","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jacc.2007.10.001","article-title":"2007 Focused update of the ACC\/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"51","author":"Antman","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2010.06.039_bb0015","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2010.06.039_bb0020","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2010.06.039_bb0025","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2010.06.039_bb0030","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"French Registry of Acute ST-Elevation and Non\u2013ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2010.06.039_bb0035","first-page":"600","article-title":"Clopidogrel response variability and future therapies: clopidogrel: does one size fit all?","volume":"114","author":"O'Donoghue","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2010.06.039_bb0040","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","article-title":"Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives","volume":"49","author":"Angiolillo","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2010.06.039_bb0045","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jacc.2008.11.030","article-title":"Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis","volume":"53","author":"Sibbing","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2010.06.039_bb0050","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jacc.2006.06.065","article-title":"Impact of the degree of periinterventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement","volume":"48","author":"Hochholzer","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2010.06.039_bb0055","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/j.1538-7836.2009.03500.x","article-title":"The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non\u2013ST acute coronary syndrome","volume":"7","author":"Fr\u00e9re","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2010.06.039_bb0060","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa012843","volume":"346","author":"Morice","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2010.06.039_bb0065","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/eurheartj\/ehp041","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention","volume":"30","author":"Sibbing","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2010.06.039_bb0070","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0735-1097(00)01014-7","article-title":"Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting","volume":"36","author":"Kastrati","year":"2000","journal-title":"J AM Coll Cardiol"},{"key":"10.1016\/j.ahj.2010.06.039_bb0075","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJMoa0801485","article-title":"Drug-eluting or bare-metal stents for acute myocardial infarction","volume":"359","author":"Mauri","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2010.06.039_bb0080","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa0810116","article-title":"Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction","volume":"360","author":"Stone","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2010.06.039_bb0085","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/eurheartj\/ehi882","article-title":"Intravascular ultrasound predictors of angiographic restenosis after sirolimus-eluting stent implantation","volume":"27","author":"Hong","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2010.06.039_bb0090","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1161\/01.CIR.0000121327.67756.19","article-title":"Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for restenosis","volume":"109","author":"Fujii","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2010.06.039_bb0095","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1050-3862(98)00019-9","article-title":"Allelic discrimination using fluorogenic probes and the 5\u2032 nuclease assay","volume":"14","author":"Livak","year":"1999","journal-title":"Genet Anal"},{"issue":"Suppl. 1","key":"10.1016\/j.ahj.2010.06.039_bb0100","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S1875-2136(09)72170-9","article-title":"A037 Impact of the CYP2C19*17 allele on platelet response to clopidogrel in patients suffering from non\u2013ST elevation acute coronary syndrome","volume":"102","author":"Fr\u00e9re","year":"2009","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.ahj.2010.06.039_bb0105","unstructured":"Bhatt DL, et al. Charisma genomics substudy: evaluation of the CYP2C19 polymorphism in a prospective, randomized, placebo-controlled trial of chronic clopidogrel use for primary and secondary prevention. TCT2009; Plenary Session XII."},{"key":"10.1016\/j.ahj.2010.06.039_bb0110","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.ahj.2005.08.002","volume":"151","author":"Sch\u00fchlen","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2010.06.039_bb0115","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jcmg.2009.01.011","article-title":"One step forward and two steps back with drug-eluting-stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis","volume":"2","author":"Nakazawa","year":"2009","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.ahj.2010.06.039_bb0120","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870310005557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870310005557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:42:42Z","timestamp":1757569362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870310005557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0002870310005557"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2010.06.039","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2010.06.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}